Montreal, QC – Biopharmaceutical company AbbVie says it is continuing to support the Structural Genomics Consortium (SGC) by providing a cash sponsorship of $7.5 million towards open access research leading to the discovery of new medicines. The announcement coincided with meetings with Ontario and Quebec-based research leaders and AbbVie global research and development business development professionals to assess continued investment.
AbbVie has provided support to the SGC since 2012. The SGC-funded research will focus on generating chemical tools and 3-dimensional structures for relatively unexplored classes of proteins such as ion channels, solute carrier channels and those involved in epigenetic regulation. These tools will then be tested in tissues, such as blood, in order to generate high-quality data that will help scientists better understand how these proteins are involved in human diseases. Immunology and oncology are the current areas of research focus.
“In order for Ontario to thrive as a true hub for research and innovation, we not only need continued partnership between our world-class university and hospital network, but also strong public-private collaborations like what we are recognizing today between AbbVie and the Structural Genomics Consortium,” said Reza Moridi, Ontario’s minister of research and innovation.